Media Articles Related to Nucynta (Tapentadol)
Patients with painful facial nerve disorder benefit from nonsurgical Gamma Knife stereotactic radiosurgery
Source: Health News from Medical News Today [2014.03.01]
Research by Beaumont Health System radiation oncologists and neurosurgeons found that symptoms of trigeminal neuralgia, or TN, a nerve disorder causing severe facial pain, were reduced in those treated with Gamma Knife stereotactic radiosurgery. The results were published recently in the journal Clinical Neurology and Neurosurgery.TN is a disorder of the trigeminal nerve, which is responsible for feeling in the face. In most cases, the facial pain is caused by a blood vessel pressing on the nerve.
Teenagers With Fibromyalgia Unlikely to 'Outgrow' the Pain
Source: Medscape Medical News Headlines [2014.02.28]
Half of adolescents with juvenile-onset fibromyalgia met diagnostic criteria for adult fibromyalgia within 6 years.
Medscape Medical News
Nighttime finger splints can ease arthritis pain
Source: Yahoo Health News [2014.02.28]
By Ronnie Cohen NEW YORK (Reuters Health) - Inexpensive splints worn nightly can reduce the pain of hand osteoarthritis, a chronic ailment that affects a majority of older adults, a new study shows. "It's a well-tolerated, safe and chea...
FDA-Approved Painkiller Zohydro Concerns Critics
Source: MedicineNet Chronic Pain Specialty [2014.02.28]
Title: FDA-Approved Painkiller Zohydro Concerns Critics
Category: Health News
Created: 2/28/2014 11:00:00 AM
Last Editorial Review: 2/28/2014 12:00:00 AM
New research could signal progress in osteoarthritis pain relief
Source: Arthritis / Rheumatology News From Medical News Today [2014.02.27]
Researchers from the Arthritis Research UK Pain Centre at The University of Nottingham have discovered a new way to potentially block the chronic and often debilitating pain affecting osteoarthritis sufferers.
Published Studies Related to Nucynta (Tapentadol)
Effect of tapentadol extended release on productivity: results from an analysis
combining evidence from multiple sources. 
OBJECTIVE: To compare the effects of tapentadol-extended release versus
oxycodone-controlled release for pain relief on productivity by combining
evidence from different sources.
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
INTRODUCTION: Two randomized, double-blind, placebo-controlled studies in acute and chronic pain treatment, powered to assess noninferiority of the efficacy of tapentadol immediate release (IR) (50 mg, 75 mg) versus oxycodone hydrochloride (HCl) IR (10 mg), established comparable efficacy of tapentadol IR with oxycodone HCl IR, and suggested tapentadol IR's improved gastrointestinal tolerability. The impact of these equianalgesic doses of tapentadol and oxycodone HCl on bowel function and gastrointestinal tolerability was then directly assessed in the current study, using a validated bowel function diary to comprehensively assess opioid-induced constipation symptoms and outcomes... CONCLUSION: Tapentadol IR (50 mg, 75 mg) consistently demonstrated superior gastrointestinal tolerability, including for the most commonly reported events, such as nausea, vomiting, and constipation at doses that provide comparable efficacy with oxycodone HCl IR 10 mg. These findings validate and extend the tolerability findings of the two earlier studies that established comparable efficacy of these tapentadol and oxycodone HCl doses.
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2011.01]
CONCLUSIONS: Compared with placebo, tapentadol ER 100-250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain 1 , 2 and was well-tolerated by patients with painful DPN.
Post hoc analyses of data from a 90-day clinical trial evaluating the
tolerability and efficacy of tapentadol immediate release and oxycodone immediate
release for the relief of moderate to severe pain in elderly and nonelderly
and nonelderly patients... CONCLUSIONS: Tapentadol IR was safe and effective for the relief of lower back
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2010.12.02]
Abstract Objective: Painful diabetic peripheral neuropathy (DPN) may not be adequately managed with available therapeutic options. This phase III, randomized-withdrawal, placebo-controlled trial evaluated the safety and efficacy of tapentadol extended release (ER) for relieving painful DPN... Conclusions: Compared with placebo, tapentadol ER 100-250 mg bid provided a statistically significant difference in the maintenance of a clinically important improvement in pain 1 , 2 and was well-tolerated by patients with painful DPN.
Clinical Trials Related to Nucynta (Tapentadol)
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin [Recruiting]
The main objective of the study is to evaluate the effectiveness, safety, and tolerability
of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a
combination of tapentadol PR (300 mg per day) and pregabalin (to 300 mg per day) in subjects
requiring additional analgesia after titration to tapentadol PR 300 mg per day.
This is a clinical effectiveness trial designed to establish a link between anticipated
clinical outcomes and the clinical practice by means of selected measures of clinical and
subject reported outcomes. Since, severe low back pain with a neuropathic component, the
targeted study population, is frequently treated with a combination therapy (monotherapy is
often not effective enough) it is of interest to determine if tapentadol alone (combining 2
mechanisms of action in a single molecule) could be as effective as a combination of
tapentadol plus pregabalin. Furthermore, the tolerability profiles of monotherapy versus
combination are of interest.
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain [Recruiting]
Evaluate how NUCYNTA (tapentadol) immediate release (IR) compares with oxycodone IR in the
treatment of acute low back pain.
A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy [Recruiting]
The purpose of this study is to demonstrate the efficacy of at least 1 dose of tapentadol IR
50 mg and/or 75 mg versus placebo using the sum of pain intensity difference at 48 hours
(SPID48) to measure analgesic effect in Korean patients with acute pain following
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain [Not yet recruiting]
A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain [Not yet recruiting]
Reports of Suspected Nucynta (Tapentadol) Side Effects
Drug Ineffective (20),
Confusional State (17),
Feeling Abnormal (17),
Withdrawal Syndrome (16),
Anxiety (14), more >>